The extended 4-year follow-up results of the ELOQUENT-2 trial
The extended 4-year follow-up results of the ELOQUENT-2 trial |
|
https://doi.org/10.18632/oncotarget.26527
Maria Gavriatopoulou,
Evangelos Terpos,
and Meletios Athanasios Dimopoulos
|
| 82-83 |
We shall overcome (drug resistance) some day
We shall overcome (drug resistance) some day |
|
https://doi.org/10.18632/oncotarget.26550
Geeta G. Sharma,
and Luca Mologni
|
| 84-85 |
| AI for medical use |
|
https://doi.org/10.18632/oncotarget.26556
Masamitsu Konno,
and Hideshi Ishii
|
| 86-87 |
Association between thyroid function and diabetic nephropathy in euthyroid subjects with type 2 diabetes mellitus: a cross-sectional study in China
Association between thyroid function and diabetic nephropathy in euthyroid subjects with type 2 diabetes mellitus: a cross-sectional study in China |
|
https://doi.org/10.18632/oncotarget.26265
Jian Wang,
Huiqin Li,
Mingjuan Tan,
Gu Gao,
Ying Zhang,
Bo Ding,
Xiaofei Su,
Xiaocen Kong,
and Jianhua Ma
|
| 88-97 |
Chemerin acts via CMKLR1 and GPR1 to stimulate migration and invasion of gastric cancer cells: putative role of decreased TIMP-1 and TIMP-2
Chemerin acts via CMKLR1 and GPR1 to stimulate migration and invasion of gastric cancer cells: putative role of decreased TIMP-1 and TIMP-2 |
|
https://doi.org/10.18632/oncotarget.26414
J. Dinesh Kumar,
Iman Aolymat,
Laszlo Tiszlavicz,
Zita Reisz,
Hanan M. Garalla,
Rob Beynon,
Deborah Simpson,
Graham J. Dockray,
and Andrea Varro
|
| 98-112 |
Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies
Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies |
|
https://doi.org/10.18632/oncotarget.26451
Ashleigh C. McEvoy,
Michelle R. Pereira,
Anna Reid,
Robert Pearce,
Lester Cowell,
Zeyad Al-Ogaili,
Muhammad A. Khattak,
Michael Millward,
Tarek M. Meniawy,
Elin S. Gray,
and Melanie Ziman
|
| 113-122 |
RASSF1C regulates miR-33a and EMT marker gene expression in lung cancer cells
RASSF1C regulates miR-33a and EMT marker gene expression in lung cancer cells |
|
https://doi.org/10.18632/oncotarget.26498
Yousef G. Amaar,
and Mark E. Reeves
|
| 123-132 |
Implication of calcium activated RasGRF2 in Annexin A6-mediated breast tumor cell growth and motility
Implication of calcium activated RasGRF2 in Annexin A6-mediated breast tumor cell growth and motility |
|
https://doi.org/10.18632/oncotarget.26512
Diva S. Whalen,
Sarrah E. Widatalla,
Olga Y. Korolkova,
Gladys S. Nangami,
Heather K. Beasley,
Stephen D. Williams,
Carlos Virgous,
Brian D. Lehmann,
Josiah Ochieng,
and Amos M. Sakwe
|
| 133-151 |
Small molecule targeted NIR dye conjugate for imaging LHRH receptor positive cancers
Small molecule targeted NIR dye conjugate for imaging LHRH receptor positive cancers |
|
https://doi.org/10.18632/oncotarget.26520
Jyoti Roy,
Miranda Kaake,
and Philip S. Low
|
| 152-160 |
Low-dose eribulin reduces lung metastasis of osteosarcoma in vitro and in vivo
Low-dose eribulin reduces lung metastasis of osteosarcoma in vitro and in vivo |
|
https://doi.org/10.18632/oncotarget.26536
Kenta Watanabe,
Yoshihiro Yui,
Satoru Sasagawa,
Kayo Suzuki,
Masahiko Kanamori,
Taketoshi Yasuda,
and Tomoatsu Kimura
|
| 161-174 |
Photo-immune therapy with liposomally formulated phospholipid-conjugated indocyanine green induces specific antitumor responses with heat shock protein-70 expression in a glioblastoma model
Photo-immune therapy with liposomally formulated phospholipid-conjugated indocyanine green induces specific antitumor responses with heat shock protein-70 expression in a glioblastoma model |
|
https://doi.org/10.18632/oncotarget.26544
Sayaka Shibata,
Natsuki Shinozaki,
Akiko Suganami,
Shiro Ikegami,
Yuki Kinoshita,
Ryozo Hasegawa,
Hirata Kentaro,
Yoshiharu Okamoto,
Ichio Aoki,
Yutaka Tamura,
and Yasuo Iwadate
|
| 175-183 |
Failures in preclinical and clinical trials of c-Met inhibitors: evaluation of pathway activity as a promising selection criterion
Failures in preclinical and clinical trials of c-Met inhibitors: evaluation of pathway activity as a promising selection criterion |
|
https://doi.org/10.18632/oncotarget.26546
Veronica S. Hughes,
and Dietmar W. Siemann
|
| 184-197 |
Molecular subtypes of triple-negative breast cancer in women of different race and ethnicity
Molecular subtypes of triple-negative breast cancer in women of different race and ethnicity |
|
https://doi.org/10.18632/oncotarget.26559
Yuan Chun Ding,
Linda Steele,
Charles Warden,
Sharon Wilczynski,
Joanne Mortimer,
Yuan Yuan,
and Susan L. Neuhausen
|
| 198-208 |
Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis
Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis |
|
https://doi.org/10.18632/oncotarget.26541
Luigi Cavanna,
Chiara Citterio,
and Elena Orlandi
|
| 209-215 |
Circulating mediators of remote ischemic preconditioning: search for the missing link between non-lethal ischemia and cardioprotection
Circulating mediators of remote ischemic preconditioning: search for the missing link between non-lethal ischemia and cardioprotection |
|
https://doi.org/10.18632/oncotarget.26537
Muntasir Billah,
Anisyah Ridiandries,
Usaid Allahwala,
Harshini Mudaliar,
Anthony Dona,
Stephen Hunyor,
Levon M. Khachigian,
and Ravinay Bhindi
|
| 216-244 |
ROS1-GOPC/FIG: a novel gene fusion in hepatic angiosarcoma
ROS1-GOPC/FIG: a novel gene fusion in hepatic angiosarcoma |
|
https://doi.org/10.18632/oncotarget.26521
Eric I. Marks,
Sahithi Pamarthy,
Don Dizon,
Ari Birnbaum,
Evgeny Yakirevich,
Howard Safran,
and Benedito A. Carneiro
|
| 245-251 |
Correction: Clinical characteristics and prognoses of patients treated surgically for metastatic lung tumors
Correction: Clinical characteristics and prognoses of patients treated surgically for metastatic lung tumors |
|
https://doi.org/10.18632/oncotarget.26575
Xiaoliang Zhao,
Xiaohua Wen,
Wei Wei,
Yulong Chen,
Jianquan Zhu,
and Changli Wang
|
| 252-252 |
Correction: Incidence and risk of regorafenib-induced hepatotoxicity
Correction: Incidence and risk of regorafenib-induced hepatotoxicity |
|
https://doi.org/10.18632/oncotarget.26576
Bin Zhao,
and Hong Zhao
|
| 253-253 |
Correction: Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib
Correction: Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib |
|
https://doi.org/10.18632/oncotarget.26577
Bin Zhao,
and Hong Zhao
|
| 254-254 |
